Human Tissues, Lipidomics, and Proteomics Core

人体组织、脂质组学和蛋白质组学核心

基本信息

批准号：
10628988
负责人：
Jose Orlando Aleman
金额：
$ 23.97万
依托单位：
NYU LONG ISLAND SCHOOL OF MEDICINE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-05-01 至 2028-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10628988
关键词：
Adipocytes Adipose tissue Apolipoproteins Apolipoproteins B Arterial Fatty Streak Atherosclerosis Basic Science Biogenesis Bioinformatics Biological Assay Biology Body Weight decreased Cardiovascular Diseases Cardiovascular system Catabolism Centrifugation Ceramides Clinical Communities Complement Data Data Set Diabetes Mellitus Family Fasting Gastrectomy Goals Health Human Hypertriglyceridemia Individual Institution Laboratories Lasers Lipids Lipoproteins Liver Macrophage Mass Spectrum Analysis Metabolism Methods Molecular Molecular Sieve Chromatography Mus Obesity Outcome Plasma Procedures Process Protein Family Proteins Proteomics Regulation Research Research Personnel Risk Risk Marker Risk Reduction Role Sampling Services Standardization Systems Biology Technology Tissues Translating Triglycerides Ultracentrifugation analytical method analytical tool bioinformatics tool cardiovascular disorder risk clinical application clinical practice clinical risk clinically relevant cohort cost effectiveness extracellular vesicles human tissue instrumentation interest lipidomics metabolomics mouse model novel particle phenotypic data pre-clinical

项目摘要

SUMMARY – HUMAN TISSUES, LIPOPROTEINS, LIPIDOMICS, & PROTEOMICS CORE (C2) The Human Tissues, Lipoproteins, Lipidomics, and Proteomics Core (Core 2, C2) will focus on providing human tissues and analytical capabilities to all three projects to enhance translatability of mouse studies proposed in P1–P3 to clinical practice in humans. In parallel, Core 2 will provide lipoprotein, lipidomic, and proteomic analyses currently not provided by our institutional Metabolomics Core. The cardiovascular research community has shown many important correlations between clinical outcomes and the plasma levels of atherogenic particles of different densities, as determined by ultracentrifugation. More detailed analyses are now uncovering additional risk for cardiovascular disease (CVD) within these particles, such as the content of apoC3 and ceramides. For this PPG, Core 2 will provide a more granular analysis of lipoproteins isolated by centrifugation and size exclusion chromatography through both directed and unbiased lipidomic and proteomic analyses of these particles. In addition, clinical samples (sera, liver, adipose) obtained by the core director will be provided to investigators in all three projects. These services will avoid the need for PPG investigators to maintain the required instrumentation in their own laboratories or use expensive commercial services. By centralizing and standardizing procedures, Core 2 provides a common set of analytical tools to provide a unified understanding of molecular mechanisms involved in pathophysiologic processes of atherosclerosis, macrophage biology, regulation of triglyceride-rich lipoproteins, and obesity. By complementing and integrating with the service provided by Core 1, Core 2 staff also provide bioinformatics support to analyze and interpret proteomic and lipidomic data sets, making Core 2 capabilities available to PPG investigators with little background or expertise in these analytical technologies. A key long-term goal is to integrate quantitative analyses of lipidomic data with functional studies to provide a systems biology view of diabetes-related cardiovascular disease. Core 2 will also develop new analytical methods tailored to specific research objectives of PPG investigators. Specifically, we will obtain and use standards to quantify and discover candidate lipids whose role in atherosclerosis is being investigated. These methods will be extensively used by PPG investigators. Core 2 will offer these services with optimal efficiency and cost-effectiveness, avoiding the need for individuals to pursue such analyses outside the PPG.

摘要 – 人体组织、脂蛋白、脂质组学和蛋白质组学核心 (C2) 人体组织、脂蛋白、脂质组学和蛋白质组学核心（核心 2，C2）将重点关注为所有三个项目提供人体组织和分析能力，以增强可翻译性与此同时，Core 2 将把 P1-P3 中提出的小鼠研究应用于人类临床实践。提供我们机构目前未提供的脂蛋白、脂质组学和蛋白质组学分析代谢组学核心。心血管研究界已经展示了许多重要的成果。临床结果与血浆致动脉粥样硬化颗粒水平之间的相关性现在通过超速离心确定不同的密度。揭示这些颗粒中心血管疾病 (CVD) 的额外风险，例如对于该 PPG，Core 2 将提供更精细的 apoC3 和神经酰胺含量分析。通过离心和尺寸排阻色谱法分离脂蛋白此外，还对这些颗粒进行公正的脂质组学和蛋白质组学分析。核心主任获得的（血清、肝脏、脂肪）将提供给所有三个领域的调查人员这些服务将避免 PPG 调查员维护所需的项目。通过集中化在自己的实验室中使用仪器或使用昂贵的商业服务。和标准化程序，Core 2 提供了一套通用的分析工具来提供对参与病理生理过程的分子机制的统一理解动脉粥样硬化、巨噬细胞生物学、富含甘油三酯的脂蛋白的调节和肥胖。为了补充和整合核心 1 提供的服务，核心 2 员工还提供生物信息学支持分析和解释蛋白质组和脂质组数据集，使 Core 缺乏这些背景或专业知识的 PPG 调查人员可以使用 2 种功能分析技术的一个关键长期目标是整合脂质组学的定量分析。数据与功能研究提供糖尿病相关心血管的系统生物学观点 Core 2 还将开发针对特定研究目标的新分析方法。具体来说，我们将获取并使用标准来量化和发现。正在研究这些方法在动脉粥样硬化中的作用的候选脂质。通常由 PPG 调查人员使用 Core 2 将以最佳效率提供这些服务。和成本效益，避免个人需要在外部进行此类分析 P.P.G.